(December 02 18:12) Forbes.com
The treatment, co-developed by GSK, gained approval from the U.K’s medicines regulator after a clinical trial showed a single dose slashed the risk of hospitalisation and death by 79% in high-risk adults with symptomatic infection.
You can find the original article
here